What is claimed is:

1. A combination comprising a first antibody or antigen-binding fragment thereof that binds specifically to C5, and a second antibody or antigen-binding fragment thereof that binds specifically to C5;

wherein the first antibody or antigen-binding fragment thereof and the second antibody or antigen-binding fragment thereof do not compete for binding to C5,

wherein the first antibody or antigen-binding fragment thereof comprises a heavy chain variable region (V_H) comprising three heavy chain complementarity determining regions (CDRs) (CDR-H1, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 19, and

a light chain variable region (V_L) comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEQ ID NO: 27;

wherein the second antibody or antigen-binding fragment thereof is an IgG4 antibody or IgG4 variant thereof and blocks about 80% or less of alternative pathway-mediated hemolysis of rabbit red blood cells *in vitro* in the presence of normal human serum; and

wherein at a 1:1 molar ratio of antibodies or antigen-binding fragments thereof, the combination completely inhibits alternative pathway-mediated hemolysis of rabbit red blood cells *in vitro* in the presence of normal human serum.

2. The combination of claim l, wherein the second antibody or antigen-binding fragment thereof comprises

a V_H comprising three heavy chain complementarity determining regions (CDRs) (CDR-Hl, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 3, and

a V_L comprising three light chain CDRs (CDR-Ll, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEQ ID NO: 11.

3. The combination of claim 1, wherein the second antibody or antigen-binding fragment thereof comprises

a V_H comprising three heavy chain complementarity determining regions (CDRs) (CDR-Hl, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEO ID NO: 35, and

a V_L comprising three light chain CDRs (CDR-Ll, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEO ID NO: 43.

4. The combination of claim 1, wherein:

the second antibody or antigen-binding fragment thereof comprises

a V_H comprising three heavy chain CDRs (CDR-H1, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 51, and

a V_L comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEQ ID NO: 59.

5. The combination of claim 4, wherein:

the second antibody or antigen-binding fragment thereof comprises a V_H comprising three heavy chain CDRs (CDR-H1, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 67 and

a V_L comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEQ ID NO: 75.

6. The combination of claim 4, wherein:

the second antibody or antigen-binding fragment thereof comprises

a V_H comprising three heavy chain CDRs (CDR-H1, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 87, and

a V_L comprising three light chain CDRs (CDR-L1, CDR-L2, and CDR-L3) of a V_L that comprises the amino acid sequence set forth in SEQ ID NO: 95.

7. The combination of claim 1, which comprises a further therapeutic agent.

8. The combination of claim 1, which comprises a further therapeutic agent which is an antibody or antigen-binding fragment that specifically binds to C5.

9. The combination of claim 1, which comprises a further therapeutic agent which is an anti-coagulant, a thrombin inhibitor, an anti-inflammatory drug, an antihypertensive, an immunosuppressive agent, a fibrinolytic agent, a lipid-lowering agent, an inhibitor of hydroxymethylglutaryl CoA reductase, an anti-CD20 agent, an anti-TNFα agent, an anti-seizure agent, a C3 inhibitor or an anti-thrombotic agent.

10. A method for making the combination of claim 1, comprising co-packaging:
the first antibody or antigen-binding fragment thereof; and
the second antibody or antigen-binding fragment thereof,
into a kit.

11. A method for making the combination of claim 1, comprising co-formulating:
the first antibody or antigen-binding fragment thereof;
the second antibody or antigen-binding fragment thereof; and
a pharmaceutically acceptable carrier,
into a single pharmaceutical formulation.

12. A combination which is the product of the method of claim 10.

13. The method of claim 10, further comprising co-packaging one or more further therapeutic agents into the kit.

14. The method of claim 11, further comprising co-formulating one or more further therapeutic agents into the formulation.

15. The method of claim 11, further comprising incorporating the formulation into a device or vessel.

16. The combination of claim l, wherein the second antibody or antigen-binding fragment thereof comprises

a heavy chain variable region (V_H) comprising three heavy chain complementarity determining regions (CDRs) (CDR-Hl, CDR-H2, and CDR-H3) of a V_H that comprises the amino acid sequence set forth in SEQ ID NO: 103, and

a light chain variable region (V_L) comprising three light chain CDRs (CDR-Ll, CDR-L2, and CDR-L3) of a light chain variable region that comprises the amino acid sequence set forth in SEQ ID NO: 95.